Symptomatology during previous SARS-CoV-2 infection and serostatus before vaccination influence the immunogenicity of BNT162b2 COVID-19 mRNA vaccine.
Nantel S, Bourdin B, Adams K, Carbonneau J, Rabezanahary H, Hamelin MÈ, McCormack D, Savard P, Longtin Y, Cheng MP, De Serres G, Corbeil J, Gilca V, Baz M, Boivin G, Quach C, Decaluwe H.
Nantel S, et al. Among authors: hamelin me.
Front Immunol. 2022 Oct 14;13:930252. doi: 10.3389/fimmu.2022.930252. eCollection 2022.
Front Immunol. 2022.
PMID: 36311736
Free PMC article.